Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Stock Information for SI-BONE Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SI-BONE Inc.

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.